FY2025 · ended Mar 31, 2025 · Revenue $1.27M, -5.5% YoY · Filed Mar 18, 2026
IGC Pharma, Inc. (IGC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Mar 31, 2025, it reported revenue of $1.3 million and a net loss of $7.1 million. Free cash flow was -$4.9 million. As of Jun 30, 2026 it held $1.1 million in cash and investments and $150,000 in total debt.
Revenue (TTM)
$1.17M
-1.2% vs year-ago TTM
Net income (TTM)
$-8.37M
+33.4% vs year-ago TTM
Operating cash flow (TTM)
$-4.62M
+5.0% vs year-ago TTM
Free cash flow (TTM)
$-4.67M
EPS (TTM)
$-0.09
Dividend per share
None
Shares outstanding
98.80M
+17.8% vs prior year
Net cash
$980,000
as of Jun 30, 2026
Operating margin
-729.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IGC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- MD
- Headquarters
- Potomac, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1326205
- Former names
- India Globalization Capital, Inc. (until Mar 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
FY 2021 Mar 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $1.3M | $911,000 | $397,000 | $898,000 |
| Operating income | -$7.4M | -$9.8M | -$11.6M | -$15.4M | -$8.7M |
| Net income | -$7.1M | -$13.0M | -$11.5M | -$15.0M | -$8.8M |
| Diluted EPS | -$0.09 | — | — | — | — |
| Operating cash flow | -$4.8M | -$5.2M | -$7.0M | -$7.5M | -$10.8M |
| Free cash flow | -$4.9M | -$5.3M | -$7.4M | -$7.7M | -$12.3M |
| Total assets | $8.7M | $9.9M | $17.2M | $26.8M | $35.9M |
| Total liabilities | $2.4M | $2.6M | $2.3M | $2.9M | $3.1M |
| Stockholders' equity | $6.3M | $7.3M | $14.9M | $23.9M | — |
| Cash and investments | $405,000 | $1.2M | $3.4M | $10.5M | $14.6M |
| Total debt | $240,000 | $348,000 | $484,000 | $611,000 | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 14, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 8, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Apr 20, 2026 | Apr 14, 2026 |
All 817 IGC Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.